Table 3.
Distribution of antibiotics resistance among the type of clinical and environmental samples
| Antibiotics | No. (%) ofresistant isolates (n=95) | ||||||||
|---|---|---|---|---|---|---|---|---|---|
|
| |||||||||
| Burn n=(66) | Wound n=(3) | ICU patients n=(2) | UTI n=(2) | Abscess & ulcer n=(4) | Vagina n=(4) | Hospital environment n=(14) | P value* | Odds ratio (95% C.I.†) | |
| Cefoxitin | 64 (96.96) | 3 (100) | 2 (100) | 2 (100) | 4 (100) | 4 (100) | 14 (100) | 1.000 | 1.33 (0.14–12.37) |
| Ceftriaxone | 59 (89.39) | 0 | 0 | 0 | 4 (100) | 1 (25) | 7 (5) | 0.0001 | - |
| Cefotaxime | 62 (93.93) | 0 | 0 | 0 | 2 (50) | 2 (50) | 6 (4.3) | 0.0001 | - |
| Ceftazidime | 66 (100) | 3 (100) | 2 (100) | 2 (100) | 4 (100) | 4 (100) | 13 (92.85) | 0.308 | 0.33 (0.03–4.04) |
| Cefepime | 58 (87.87) | 1 (33.33) | 1 (50) | 1 (50) | 2 (50) | 2 (50) | 7 (50) | 0.001 | 1.00 (0.11–9.23) |
| Amoxicillin/clavulanic acid | 60 (90.90) | 2 (66.66) | 1 (50) | 2 (100) | 4 (100) | 3 (75) | 12 (85.7) | 0.292 | 0.50 (0.03–7.54) |
| Ampicillin/sulbactam | 66 (100) | 3 (100) | 2 (100) | 2 (100) | 4 (100) | 4(100) | 14 (100) | - | - |
| Piperacillin | 63 (95.45) | 0 | 0 | 0 | 2 (50) | 1 (25) | 3 (21.4) | 0.0001 | - |
| Piperacillin/Tazobactam | 63 (95.45) | 0 | 0 | 0 | 1 (25) | 1(25) | 1 (7.1) | 0.0001 | - |
| Aztreonam | 59 (89.39) | 3 (100) | 1 (50) | 0 | 4 (100) | 4 (100) | 7 (50) | 0.002 | 1.22 (0.09–16.43) |
| Imipenem | 63 (95.45) | 0 | 0 | 0 | 1 (25) | 0 | 1 (7.1) | 0.0001 | 4.33 (0.21–90.85) |
| Meropenem | 63 (95.45) | 0 | 0 | 0 | 1 (25) | 0 | 1 (7.1) | 0.0001 | - |
| Colistin | 4 (6.06) | 1 (33.33) | 0 | 1 (50) | 0 | 1 (25) | 0 | 0.093 | - |
| Gentamicin | 63 (95.45) | 0 | 0 | 0 | 1 (25) | 0 | 1 (7.1) | 0.0001 | - |
| Amikacin | 63 (95.45) | 0 | 0 | 0 | 1 (25) | 0 | 2 (14.3) | 0.0001 | - |
| Ciprofloxacin | 64 (96.96) | 0 | 0 | 0 | 1 (25) | 0 | 3 (21.4) | 0.0001 | - |